Panoramic Science LLC — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$1,359,717	105
2024	Research	$766,178	109
2023	Research	$6,395	4

Breakdown

Who paid Research payments · program years 2023–2025

Bayer HealthCare Pharmaceuticals Inc. $1,104,714 141 payments
Eli Lilly and Company $790,583 8 payments
Aurinia Pharma U.S., Inc. $106,473 50 payments
Amgen Inc. $70,672 4 payments
Calliditas Therapeutics US Inc. $22,584 6 payments
CSL Behring $19,065 8 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $18,200 1 payment

Studies the money was for Research payments · program years 2023–2025

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $790,583 8 payments
2024-01-08 SUPPORT OF INVESTIGATOR / INSTITUTION SPONSORED COLLABORATIVE STUDY Panoramic Science, LLC / GEMINI-3 $632,128 4 payments
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes $352,770 88 payments
LUPKYNIS Registry Study $106,473 50 payments
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis $70,672 4 payments
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic $35,289 24 payments
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K $26,270 10 payments
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a $25,111 9 payments
Nef-403 $22,584 6 payments
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis $19,065 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.